Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

Abstract: A smart multi-car elevator system, comprising at least two hoistways, a switch mechanism, a power mechanism and multiple cars; the hoistways are internally provided with rails for the movement of the cars, the switch mechanism is provided between adjacent hoistways, the position of the cars being switched, by means of the switch mechanism, between the adjacent hoistways; the perform, driven by the power mechanism, upward or downward movement within the hoistways or switch movement between the hoistways, and the cars are driven by the power mechanism to stop at any floor for people to get in or get out the elevator. The smart multi-car elevator system is provided with multiple individually running cars within one hoistway, improving the conveying efficiency and effectively saving the building space and building cost.

Abstract: Embodiments of the present invention disclose a method and apparatus for implementing a three-dimensional panel at an IM client. The method includes: receiving request information of entering a three-dimensional panel; obtaining configuration information of the three-dimensional panel; obtaining identity information of IM contacts; and starting the three-dimensional panel according to the configuration information and displaying the identity information of the IM contacts on the three-dimensional panel. By the technical solutions provided by the present invention, the IM contacts of an IM user can be displayed on the three-dimensional panel, so that the IM user can communicate with the IM contacts in a three-dimensional scene, thereby solving the problem that the conventional panel is single and short of originality, and bringing better user experiences for the IM user.

Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C—C? loop of the D1 domain; residues 317-323, the C—C? loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C-C? loop of the D1 domain; residues 317-323, the C-C? loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C—C′ loop of the D1 domain; residues 317-323, the C—C′ loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.

Abstract: Peptide conjugates of the formula are provided (R—X)n-peptide  (I) wherein: n is from 1 to 10; X is (a) C═O, when the R—X group is attached to: (i) the N-terminus of the peptide, or (ii) a side chain of the peptide where the functional group of the side chain to which the R—X group is attached is NH2 or OH; or (b) O or NH, when the R—X group is attached to (i) the C-terminus of the peptide, or (ii) a side chain of the peptide where the functional group of the side chain to which the R—X group is attached is COOH or CONH2; and R is selected from the group consisting of C2-18 alkyl; C2-18 alkoxy; C2-14 alkylenyl containing one or two double bonds; cyclobutyl; cyclopentyl; cyclohexyl optionally monosubstituted with a C1-5 straight or branched chain alkyl group; phenyl optionally monosubstituted with a C1-5 straight or branched chain alkyl group; and benzyl.

Abstract: Substituted 4H-chromene derivatives are a new class of compounds that bind to Bcl-2 protein and induce apoptosis in tumor cells. The present invention is directed to an efficient synthetic method for the preparation of these compounds from salicylaldehyde derivatives and alkyl cyanoacetates under solid phase.

Abstract: The viral Macrophage Inflammatory Protein-II (vMIP-II) is a chemokine that interacts with the CC and CXC chemokine receptors, including the CCR5 and CXCR4 chemokine receptors. CCR5 and CXCR4 are the principal coreceptors required for cell entry of human immunodeficiency virus type 1 (HIV-1). The present invention describes a peptide fragment of the vMIP-II that prevents the HIV-1 virus from interacting with the coreceptor CXCR4, thereby preventing viral infection of that cell. These peptide fragments will serve as lead compounds for the development of therapeutic agents against HIV-1 infections.

Abstract: Synthetic peptide analogs of chemokines are designed to include the N- and C-terminal portions of the corresponding naturally occurring chemokine. In particular, synthetic peptide analogs of stromal cell-derived factor-1 (SDF-1) are effective in inhibiting HIV-1 entry and infection via the CXC chemokine receptor 4 (CXCR4). Each peptide comprises a peptide segment analog of the SDF-1 N-terminal region joined to a peptide segment analog of the SDF-1 C-terminal region. The peptides are useful for HIV treatment and prophylaxis.

Abstract: Small molecule inhibitors of Bcl-2 function are used to induce apoptosis of cells which are subject to Bcl-2, which cells are otherwise subject to Bcl-2 mediated blockage of apoptosis. The compounds are useful for treating cancer, autoimmune disorders and viral infection.

Abstract: MHC or HLA Class I peptides and compositions thereof are provided for the specific induction of apoptosis of cancer cells in a patient. Methods of treating cancer cells in patients suffering from cancer employing the MHC or HLA Class I peptides of the invention. Also provided are methods of identifying MHC or HLA Class I peptides and variants thereof capable of killing cancerous cells in vivo in a patient suffering from cancer.

Abstract: Substituted 4H-chromene derivatives are a new class of compounds that bind to Bcl-2 protein and induce apoptosis in tumor cells. The present invention is directed to an efficient synthetic method for the preparation of these compounds from salicylaldehyde derivatives and alkyl cyanoacetates under solid phase.

Abstract: MHC or HLA Class I peptides and compositions thereof are provided for the specific induction of apoptosis of cancer cells in a patient. Methods of treating cancer cells in patients suffering from cancer employing the MHC or HLA Class I peptides of the invention. Also provided are methods of identifying MHC or HLA Class I peptides and variants thereof capable of killing cancerous cells in vivo in a patient suffering from cancer.

Abstract: Compounds that inhibit CD8 mediated T cell activation and that have a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 38-46 and/or 53-56 and/or 60-67 and pharmaceutical compositions comprising such compounds are disclosed. Methods of inhibiting activation of a human T cell are disclosed. The methods comprise contacting a T cell with a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 38-46 and/or 53-56 and/or 60-67. Methods of treating an individual suspected of suffering from or susceptible to graft versus host disease and/or organ rejection are disclosed. The methods comprise administering an effective amount of a compound that inhibits CD8 mediated T cell activation and that has a molecular surface that corresponds to the molecular surface of human CD8 at amino acids 34-46 and/or 53-56 and/or 60-67.

Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4.sup.+ T cell immune responses by identifying compounds that block the interaction of CD4 and class II MHC gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4.sup.+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 500 and 150 that bind to the GFCC'C" portion of the D1 domain of human CD4 lymphocyte cell surface antigen.

Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4.sup.+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4.sup.+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C-C' loop of the D1 domain; residues 317-323, the C-C' loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.